Alnylam Pharmaceuticals | ALNY - Operating Profit


Alnylam Pharmaceuticals reported $29.4M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 17.39M 18.36M Dec/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Arrowhead Research USD 40.81M 3.3M Dec/2025
BioCryst Pharmaceuticals USD -2.54M 10.23M Dec/2024
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Ionis Pharmaceuticals USD -215M 54.82M Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.58B 879M Sep/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.5B 2.29B Dec/2025
Sarepta Therapeutics USD -410.08M 347.2M Dec/2025
Takeda JPY 168.82B 479.89B Dec/2025
Tectonic Therapeutic USD -21.89M 440K Sep/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025
Xencor USD -53.63M 6.11M Dec/2025